Literature DB >> 7667392

Reversal of toxicity using avidin-based hemoperfusion: a model system in rats using biotinylated melittin.

A M Britt1, K K Burkhart, M L Billingsley.   

Abstract

The high-affinity interaction between avidin and biotin (Kd = 10(-15)M) can be exploited to develop specific protocols for retrieval of biotinylated drugs and toxicants from biological fluids. Melittin, the main toxic component of bee venom, was biotinylated and used as a model toxicant to determine whether avidin-based extracorporeal hemoperfusion could remove biotinylated melittin and thus alter the severity of the toxic response in rats. Melittin was biotinylated using N-hydroxysuccinimide-long-chain biotin. Biotinylated melittin produced 100% lethality in rats by 120 min following four sequential intravenous injections of 1.7 mg/kg biotinylated melittin (0, 5, 20, and 35 min). An avidin hemoperfusion column was constructed (10 mg avidin/1 ml gel) and connected via the femoral vasculature to rats intoxicated with biotinylated melittin. Controls rats were hemoperfused using avidin columns blocked with d-biotin. None of the 6 rats hemoperfused using the biotin-blocked avidin column control survived, whereas 5 of 9 of the experimental rats survived to 120 min. The difference between the two survival rates was statistically significant (p < 0.0048). Thus, avidin-based hemoperfusion improved survival following biotinylated melittin toxicity and strengthens the concept that avidin-based hemoperfusion can reverse the toxicity of biotinylated toxicants.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7667392     DOI: 10.1159/000139296

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  1 in total

1.  Design of synthetic polymer nanoparticles that capture and neutralize a toxic peptide.

Authors:  Yu Hoshino; Takeo Urakami; Takashi Kodama; Hiroyuki Koide; Naoto Oku; Yoshio Okahata; Kenneth J Shea
Journal:  Small       Date:  2009-07       Impact factor: 13.281

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.